Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Innovation

Cell and gene therapies rely on the fragile integrity of life itself—a single cell surviving through an unforgiving journey from lab to patient

Bioprocessing

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy’s success.

Bioprocessing

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?

Bioprocessing

Is your process model gathering dust while real-world decisions march on without it?

Bioprocessing

Bioprocess development lies at the heart of modern biotechnology, turning innovative molecules into life-changing therapies.

Bioprocessing

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy’s success.

Bioprocessing

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?

Bioprocessing

Is your process model gathering dust while real-world decisions march on without it?

Bioprocessing

Bioprocess development lies at the heart of modern biotechnology, turning innovative molecules into life-changing therapies.

Bioprocessing

Bioreactor scale-up failures are still one of the top reasons promising cell therapies never reach the clinic. Traditional “power per volume” scale-up is often just a best guess—putting product quality and timelines at risk.

Bioprocessing

Can computational fluid dynamics (CFD) join the ranks of everyday tools in bioprocess engineering—right alongside spreadsheets and pH meters?

Data & Analytics

How do you actually measure and shrink your true environmental impact, when most data is missing and every facility operates on a different baseline?

Data & Analytics

Is your manufacturing strategy bleeding money in ways you can’t see?

Data & Analytics

Biotechnology is often perceived as a field exclusively for those with a background in biology.

Data & Analytics

Bioprocess development has long been recognized for its complexity, requiring rigorous experimentation, considerable time, and substantial resources. Yet a shift is underway.

Data & Analytics

ELISA (Enzyme-linked Immunosorbent Assay) has been a workhorse in biotech laboratories for decades.

Biotech Success

Complex automation often arrives wrapped in hype, but the reality is more nuanced.

Biotech Success

Are you struggling with automation projects that spiral into unnecessary complexity or fail to solve the real problem in bioprocessing?

Biotech Success

Biologics manufacturing success is built—not salvaged—from day one. Overlook CMC fundamentals, and you’re architecting your own failure.

Biotech Success

How solid is your CMC foundation—and what happens if it cracks under pressure?

Biotech Success

When raffinose works, when it doesn’t, and a 3-experiment protocol to validate it for your process in 8 weeks.

Biotech Success

Why pistachios sabotaged cyclists’ performance — and the raffinose mechanism behind it.

Innovation

Biotech startups face a labyrinth of decisions when it comes to manufacturing strategy.

Innovation

What if batch-to-batch variability was no longer just “part of the job” in tissue engineering and in vitro biology?

Innovation

Cell line development in biotech is a race against time and complexity, with innovators constantly seeking solutions that provide robust and scalable data for manufacturability and regulatory demands.

Innovation

Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability.

Innovation

Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.

Innovation

Imagine a delivery system that can slip straight into a cell’s membrane, bypassing the barriers that stop most genetic medicines in their tracks. While AAVs and lipid nanoparticles have charted the way for gene therapies, a new contender is emerging: proteolipid vehicles powered by viral fusion proteins.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.